Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02959944 · ClinicalTrials.gov registry record · Phase 3

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

A Phase 3 study of Chronic Graft Versus Host Disease, sponsored by Pharmacyclics.

Completed
Registry status
Phase 3
Development phase
193
Enrollment target
20
Study locations

NCT02959944 is a Phase 3 study of Chronic Graft Versus Host Disease that has completed, run by Pharmacyclics. The registered enrollment target is 193 participants, above the 110-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02959944, a Phase 3 study of Chronic Graft Versus Host Disease, has completed, sponsored by Pharmacyclics.

COMPLETED
Registry status
Phase 3
Development phase
193 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • DRUG Placebo
  • DRUG Prednisone
  • DRUG ibrutinib

Study Locations (20)

California

  • LPCH Stanford /ID# 1140-1128 - Palo Alto
  • Ucsf /Id# 1140-0003 - San Francisco
  • Stanford University/Stanford Cancer Center, Pasteur Drive /ID# 1140-0400 - Stanford

Massachusetts

  • Massachusetts General Hospital Cancer Center /ID# 1140-0020 - Boston
  • Boston Childrens Hospital /ID# 1140-1615 - Boston
  • Dana-Farber Cancer Institute /ID# 1140-0349 - Boston

Florida

  • Jackson Memorial Hospital, University of Miami /ID# 1140-0647 - Miami
  • Florida Hospital Cancer Institute/Adventist Health System/Sunbelt, Inc /ID# 1140-1121 - Orlando

Georgia

  • Emory University, Winship Cancer Institute /ID# 1140-0033 - Atlanta
  • Emory University/Winship Cancer Institute /ID# 1140-1179 - Atlanta

Illinois

  • University of Chicago /ID# 1140-0126 - Chicago
  • Loyola University /ID# 1140-0713 - Maywood

Kentucky

  • University of Kentucky /ID# 1140-1140 - Lexington
  • University of Louisville Hospital /ID# 1140-1131 - Louisville

Arizona

  • Arizona Oncology - Scottsdale - Cancer Transplant Institute Location /ID# 1140-1120 - Scottsdale

Colorado

  • UCHSC Anschultz Cancer Pavilion /ID# 1140-0068 - Aurora

Trial Details

FieldValue
Enrollment Target 193 participants
Start Date 2017-05-11
Est. Completion 2021-07-12
Phase Phase 3

Sponsor

Pharmacyclics

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02959944

The ClinicalTrials.gov registry entry for NCT02959944 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (75% higher). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02959944 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Massachusetts, Florida.

Frequently Asked Questions

What is clinical trial NCT02959944 about?

NCT02959944 is a clinical study titled "Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)". To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.

What is the current status of trial NCT02959944?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2017-05-11. Estimated completion is 2021-07-12.

What conditions does trial NCT02959944 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT02959944?

The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), ibrutinib (DRUG).

Who is sponsoring clinical trial NCT02959944?

This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02959944 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.